Identifying How The Enteric Nervous System Regulates Gut Permeability In Autism
Funder
National Health and Medical Research Council
Funding Amount
$448,643.00
Summary
This project aims to investigate causes of increased gut permeability in neurological disorders including autism and will apply neuroscience, immunological and microbiology techniques to clarify the causes of increased gut permeability in a well-characterised genetic mouse model of autism.
Modulating Inflammation As A Therapy For Harlequin Ichthyosis
Funder
National Health and Medical Research Council
Funding Amount
$718,739.00
Summary
Harlequin Ichthyosis is a severe inherited skin disease caused by mutations in a protein which regulates how skin cells control their levels of lipids. Treatments for this disease are limited and do little to improve patients condition. We believe we have found a new way to treat this condition by altering tissue inflammation. This grant will undertake important experiments aimed at developing new therapies for this currently incurable disease.
Understanding How Bcl-2 Proteins Form The Apoptotic Pores That Kill Cells
Funder
National Health and Medical Research Council
Funding Amount
$893,614.00
Summary
Programmed cell death termed apoptosis is a process our bodies use to remove cells that are a threat to our health, e.g. cancer cells. The proteins that regulate cell death are attractive targets for therapeutics that have become resistant to this defence mechanism. This study will reveal how proteins from the Bcl-2 family regulate cell death at the molecular level. Understanding this process will inform the development of drugs aimed at regulating cell death in cancer and other diseases.
What Is The Molecular Mechanism Underlying Cell Death By Necroptosis?
Funder
National Health and Medical Research Council
Funding Amount
$653,742.00
Summary
Recently, we and others have demonstrated that part of the MLKL protein is able to kill cells. This process is known to cause a number of pathologies, including those arising from stroke. Blocking this type of cell death has thus emerged as an attractive therapeutic strategy. However, precisely how MLKL kills cells remains unclear and controversial. In this project, we will resolve these controversies with the goal of an increased fundamental understanding to aid drug discovery.
Second Trimester Intra-amniotic Treatment For Early Preterm Birth
Funder
National Health and Medical Research Council
Funding Amount
$392,420.00
Summary
Preterm birth is the leading cause of neonatal death and disability in Australia today, with those born before 32 weeks' completed gestation at the highest risk. Preventing these early preterm births requires treatment of the causative uterine infection. This proposal is to conduct the first study of direct intraamniotic antibiotic treatment of uterine Ureaplasma infection in a clinically relevant, large animal model of second trimester pregnancy.